StockNews.AI
JAZZ
StockNews.AI
189 days

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

1. Jazz Pharmaceuticals will announce Q4 2024 earnings on February 25, 2025. 2. A live webcast will discuss financial results and business updates. 3. The company focuses on innovative treatments for serious diseases. 4. Jazz has a diverse portfolio in oncology, neuroscience, and sleep disorders.

Earnings
+4.2%Current Return
VS
-0.3%S&P 500
$129.9802/11 04:19 PM EDTEvent Start
$135.4402/12 11:06 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements can have varying effects; historically, market reactions differ significantly.

How important is it?

Earnings announcements are critical, yet the current impact is uncertain.

Why Short Term?

Upcoming earnings reports typically influence stock price in the short-term.

Related Companies

JAZZNDAQ
, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 full year and fourth quarter financial results and provide a business and financial update.   Audio webcast/conference call:U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 943 926Additional global dial-in numbers are available here.Passcode: 5080203 Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.  About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information. Contacts: Investors:Jeff Macdonald Executive Director, Investor RelationsJazz Pharmaceuticals plc[email protected]Ireland +353 1 634 3211U.S. +1 650 496 2717 Media:Kristin BhavnaniHead of Global Corporate CommunicationsJazz Pharmaceuticals plc[email protected]Ireland +353 1 637 2141U.S. +1 215 867 4948 SOURCE Jazz Pharmaceuticals plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News